Predictors of outcome in post-transplant lymphoproliferative disorder: An evaluation of tumor infiltrating lymphocytes in the context of clinical factors

Leukemia and Lymphoma

Volumn 50, Issue 12, 2009, Pages 2005-2012

  Richendollar, Bill G ^a   Tsao, Raymond E ^b   Elson, Paul ^a   Jin, Tao ^a   Steinle, Roxanne ^a   Pohlman, Brad ^c   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cytotoxic T cells; Prognostic factors; PTLD; Regulatory T cells

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; DOXORUBICIN; GANCICLOVIR; INTERFERON; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CHILD; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD3; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY; T-LYMPHOCYTES; TISSUE TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72949111821     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903315713     Document Type: Article

References (60)

1. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Posttransplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
2. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007;131:1209-1218.
3. Starzl TE. Discussion of Murray JE, Wilson RE, Tilney NL, et al. Five years' experience in renal transplantation with immunosuppressive drugs: Survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968;168:416.
4. Briggs JD, Canavan JS, Dick HM, et al. Influence of HLA matching and blood transfusion on renal allograft survival. Transplantation 1978;25:80-85.
5. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999;94:2208-2216.
6. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006;91:1059-1067.
7. Wigle DA, Chaparro C, Humar A, Hutcheon MA, Chan CK, Keshavjee S. Epstein-Barr virus serology and post-transplant lymphoproliferative disease in lung transplantation. Transplantation 2001;72:1783-1786.
8. Haque T, Thomas JA, Falk KI, et al. Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996;77:1169-1172.
9. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for post-transplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995;14:214-221.
10. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003;75:987-993.
11. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity? Am J Surg Pathol 2000;24:375-385.
12. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein- Barr virus: A distinct entity? J Clin Oncol 1998;16:2052-2059.
13. Birkeland SA, Hamilton-Dutoit S. Is post-transplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003;76:984-988.
14. Brouwer RM, Balk AH, Weimar W. Occurrence of lymphoproliferative disorder after heart transplantation is related to the total immunosuppressive load. Transpl Int 1992; 5(suppl 1):S259-S261.
15. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990;323:1723-1728.
16. Beveridge T, Krupp P, McKibbin C. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy. Lancet 1984;1:788.
17. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-587.
18. Hezode C, Duvoux C, Germanidis G, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 1999;30:775-778.
19. Shpilberg O, Wilson J, Whiteside TL, Herberman RB. Pretransplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: The results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk Lymphoma 1999;36: 109-121.
20. Cohen AH, Sweet SC, Mendeloff E, et al. High incidence of post-transplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 2000; 161:1252-1255.
21. Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR Jr, Whitington PF. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr 1997;131:98-104.
22. Swerdlow AJ, Higgins CD, Hunt BJ, et al. Risk of lymphoid neoplasia after cardiothoracic transplantation: A cohort study of the relation to Epstein-Barr virus. Transplantation 2000; 69:897-904.
23. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: A multiinstitutional study. Lancet 2006;367:233-239.
24. Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Post-transplant lymphoproliferative disorder: Incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003;124:1242-1249.
25. Norin S, Kimby E, Ericzon BG, et al. Post-transplant lymphoma - a single-center experience of 500 liver transplantations. Med Oncol 2004;21:273-284.
26. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: Incidence, risk factors and survival. Am J Transplant 2006;6:1017-1024.
27. Jain A, Nalesnik M, Reyes J, et al. Post-transplant lymphoproliferative disorders in liver transplantation: A 20-year experience. Ann Surg 2002;236:429-437.
28. Caillard S, Lelong C, Pessione F, Moulin B; French PTLD Working Group. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 2006;6: 2735-2742.
29. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999;94:2208-2216.
30. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004;4:222-230.
31. Paraskevas S, Coad JE, Gruessner A, et al. Post-transplant lymphoproliferative disorder in pancreas transplantation: A single-center experience. Transplantation 2005;80:613-622.
32. Cockfield SM. Identifying the patient at risk for posttransplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:70-78.
33. LaCasce AS. Post-transplant lymphoproliferative disorders. Oncologist 2006;11:674-680.
34. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006;107:3053-3057.
35. Sato T, Fujieda M, Maeda A, et al. Monitoring of Epstein- Barr virus load and killer T-cells in pediatric renal transplant recipients. Clin Nephrol 2008;70:393-403.
36. + T-cell phenotype and function, Epstein- Barr virus load, and clinical outcome in pediatric renal transplant recipients: A prospective study. Transplantation 2004;77:1706-1713.
37. Kuzushima K, Kimura H, Hoshino Y, et al. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during post-transplant lymphoproliferative disorder. J Infect Dis 2000;182:937-940.
38. + regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007;137:364-373.
39. Carreras J, Lopez-Guillermo A, Fox B, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-2964.
40. Á lvaro T, Lejeune M, Salvado M, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T Cells. Clin Cancer Res 2005;11:1467-1473.
41. Ghobrial I, Habermann T, Ristow K, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005;46:191-196.
42. Leblond V, Dhedin N, Mamzer Bruneel M, et al. Identification of prognostic factors in 61 patients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2001;19:772-778.
43. Yakirevich E, Izhak OB, Rennert G, Kovacs ZG, Resnick MB. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Mod Pathol 1999;12: 1050-1056.
44. Yakirevich E, Lefel O, Sova Y, et al. Activated status of tumour-infiltrating lymphocytes and apoptosis in testicular seminoma. J Pathol 2002;196:67-75.
45. Verdonk R, Haagsma E, Jonker M, et al. Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients. Inflamm Bowel Dis 2007;13:703-709.
46. + T cells selectively kill B lymphocytes. Blood 2006;107:3925-3932.
47. Godfrey V, Wilkinson J, Russell L. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol 1991; 138:1379-1387.
48. Buell J, Gross T, Hanaway M, et al. Chemotherapy for posttransplant lymphoproliferative disorder: The Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005;37:956-957. (Pubitemid 40590757)
49. Sharman J, Tsai D, Twist C, Horwitz SM, Jones CD, Horning SJ. Mature results of a prospective trial of rituximab in patients with post transplant lymphoproliferative disorder unresponsive or ineligible for reduced immunosuppression. Blood 2006;108:2755 (Abstract).
50. Elstrom R, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6:569-576.
51. Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007;86:599-607.
52. Swinnen L, Mullen G, Carr T, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86:3333-3340.
53. Trappe R, Choquet S, Oertel S, et al. Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD - a new standard in therapy? Blood 2007;110: (Abstract 390).
54. Budhu A, Forgues M, Ye Q, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111.
55. Bates G, Fox S, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-5380.
56. Grabenbauer G, Lahmer G, Distel L, Niedobitek G. Tumorinfiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006;12:3355-3360.
57. + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007;128:958-965.
58. Markasz L, Vanherberghen B, Flaberg E, et al. NK cellmediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab. Biomed Pharmacother 2009;63:413-420.
59. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands. Cancer Res 2008;68:8437-8445.
60. Nalesnik MA, Zeevi A, Randhawa PS, et al. Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clin Transplant 1999;13:39-44.